Streptozocin + Doxorubicin Regimen (STZ + DOXO) (Zanosar + Adriamycin) — Clinical FAQs

Question 1

What is Streptozocin + Doxorubicin Regimen (STZ + DOXO) FDA-approved to treat?

Accepted Answer

Streptozocin + Doxorubicin Regimen (STZ + DOXO) is FDA-approved for the following oncology indications: 1. Metastatic islet cell carcinoma of the pancreas — streptozocin is FDA-approved for use in combination with doxorubicin for this indication (approved 1982, based on the Moertel/ECOG data).

Question 2

How does Streptozocin + Doxorubicin Regimen (STZ + DOXO) work (mechanism of action)?

Accepted Answer

Mechanistically complementary two-drug combination for advanced pancreatic neuroendocrine tumors (pNETs). Streptozocin is a nitrosourea-type alkylating agent that exploits GLUT2-mediated uptake into pancreatic islet-derived cells, alkylating DNA at O6-guanine and causing strand breaks. Doxorubicin is an anthracycline that intercalates into DNA, inhibits topoisomerase II, and generates reactive oxygen species — mechanisms entirely distinct from streptozocin alkylation. The two agents provide non-overlapping DNA damage pathways, and doxorubicin has been observed to prolong streptozocin half-life by competing for hepatic metabolism, potentially increasing streptozocin exposure. GLUT2-mediated selective uptake of streptozocin into pNET cells provides some degree of tumor-cell enrichment not available with doxorubicin alone.

Question 3

How is Streptozocin + Doxorubicin Regimen (STZ + DOXO) administered?

Accepted Answer

Streptozocin + Doxorubicin Regimen (STZ + DOXO) is administered Intravenous (IV). Standard Moertel regimen (5-day schedule): Streptozocin 500 mg/m² IV daily on days 1–5 + Doxorubicin 50 mg/m² IV on days 1 and 22, repeated every 6 weeks (42-day cycle).

Question 4

What are the most common side effects of Streptozocin + Doxorubicin Regimen (STZ + DOXO)?

Accepted Answer

The most commonly reported side effects of Streptozocin + Doxorubicin Regimen (STZ + DOXO) (≥10% incidence) include: Severe nausea and vomiting (>90% with streptozocin; highly emetogenic; combination worsens emetic burden), Myelosuppression — neutropenia, thrombocytopenia, anemia (primarily from doxorubicin; nadir days 10–14), Renal tubular dysfunction — glucosuria, proteinuria, hypophosphatemia (streptozocin), Alopecia (complete; doxorubicin), Mucositis (doxorubicin) and others (9 total). Consult your oncologist for complete prescribing information.

Question 5

Does Streptozocin + Doxorubicin Regimen (STZ + DOXO) have a black box warning?

Accepted Answer

Yes. Streptozocin + Doxorubicin Regimen (STZ + DOXO) carries FDA black box warning(s) regarding: 1. Streptozocin — Renal Toxicity (Dose-Limiting): Cumulative nephrotoxicity including azotemia, Fanconi syndrome (tubular acidosis, glucosuria, phosphaturia, aminoaciduria), and irreversible renal failure. Monitor renal function before each course; reduce or discontinue based on renal impairment. Do not combine with other nephrotoxic agents. 2. Streptozocin — Hepatotoxicity: Monitor LFTs before each cycle. 3. Streptozocin — Myelosuppression: Obtain CBC before each course. 4. Doxorubicin — Cardiotoxicity: Cumulative dose-dependent cardiomyopathy and congestive heart failure. Risk rises sharply above 450 mg/m² cumulative dose. Baseline and periodic cardiac function assessment required. 5. Doxorubicin — Severe Myelosuppression: Profound neutropenia and thrombocytopenia; nadir typically days 10–14. 6. Doxorubicin — Vesicant: Severe local tissue necrosis on extravasation; use only through a well-confirmed IV access. 7. Doxorubicin — Secondary AML/MDS: Risk of treatment-related leukemia with cumulative anthracycline exposure.

Question 6

Is Streptozocin + Doxorubicin Regimen (STZ + DOXO) safe during pregnancy?

Accepted Answer

Streptozocin + Doxorubicin Regimen (STZ + DOXO) pregnancy safety: Category D — Both streptozocin and doxorubicin are teratogenic and embryotoxic. Effective contraception required during treatment and for ≥6 months after the last doxorubicin dose (due to gonadal toxicity). Do not use during pregnancy unless benefit clearly outweighs risk.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Streptozocin + Doxorubicin Regimen (STZ + DOXO) — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms